PT1613288E - Composições farmacêuticas sólidas que compreendem um agonista dos receptores de s1p e um álcool de açúcar - Google Patents

Composições farmacêuticas sólidas que compreendem um agonista dos receptores de s1p e um álcool de açúcar Download PDF

Info

Publication number
PT1613288E
PT1613288E PT04725895T PT04725895T PT1613288E PT 1613288 E PT1613288 E PT 1613288E PT 04725895 T PT04725895 T PT 04725895T PT 04725895 T PT04725895 T PT 04725895T PT 1613288 E PT1613288 E PT 1613288E
Authority
PT
Portugal
Prior art keywords
receptor agonist
sugar alcohol
solid pharmaceutical
pharmaceutical compositions
pharmaceutical composition
Prior art date
Application number
PT04725895T
Other languages
English (en)
Inventor
Tomoyuki Oomura
Madhusudhan Pudipeddi
Alan Edward Royce
Colleen Ruegger
Masaki Sasaki
Tokuhiro Tamura
Original Assignee
Novartis Ag
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1613288(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Mitsubishi Tanabe Pharma Corp filed Critical Novartis Ag
Publication of PT1613288E publication Critical patent/PT1613288E/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Surgery (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Transplantation (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
PT04725895T 2003-04-08 2004-04-06 Composições farmacêuticas sólidas que compreendem um agonista dos receptores de s1p e um álcool de açúcar PT1613288E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08

Publications (1)

Publication Number Publication Date
PT1613288E true PT1613288E (pt) 2009-02-25

Family

ID=32326722

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04725895T PT1613288E (pt) 2003-04-08 2004-04-06 Composições farmacêuticas sólidas que compreendem um agonista dos receptores de s1p e um álcool de açúcar

Country Status (42)

Country Link
US (11) US20060275357A1 (pt)
EP (5) EP2316431B1 (pt)
JP (3) JP5495467B2 (pt)
KR (3) KR20110005320A (pt)
CN (2) CN1767819B (pt)
AR (3) AR043987A1 (pt)
AT (3) AT501681B1 (pt)
AU (1) AU2004228929B2 (pt)
BE (2) BE1015972A5 (pt)
BR (1) BRPI0409250B8 (pt)
CA (2) CA2707750A1 (pt)
CL (2) CL2004000745A1 (pt)
CY (3) CY1110260T1 (pt)
DE (4) DE202004021680U1 (pt)
DK (2) DK1613288T3 (pt)
EC (1) ECSP056090A (pt)
ES (3) ES2228282B1 (pt)
FR (2) FR2854073B1 (pt)
GB (1) GB2400318B (pt)
GR (1) GR1005052B (pt)
HK (3) HK1071685A1 (pt)
HR (3) HRP20050886B1 (pt)
HU (2) HUE028247T2 (pt)
IL (3) IL170888A (pt)
IS (2) IS2682B (pt)
IT (1) ITMI20040682A1 (pt)
LU (1) LU91867I2 (pt)
MA (1) MA27729A1 (pt)
MX (1) MXPA05010860A (pt)
MY (1) MY141249A (pt)
NO (4) NO329332B1 (pt)
NZ (3) NZ542622A (pt)
PE (5) PE20090743A1 (pt)
PL (2) PL2316431T3 (pt)
PT (1) PT1613288E (pt)
RU (5) RU2358716C2 (pt)
SG (1) SG175449A1 (pt)
SI (2) SI1613288T1 (pt)
TN (1) TNSN05256A1 (pt)
TW (1) TWI332847B (pt)
WO (1) WO2004089341A1 (pt)
ZA (1) ZA200507394B (pt)

Families Citing this family (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1773307T3 (pl) * 2004-07-30 2015-03-31 Novartis Ag Preparaty 2-amino-1,3-propanodioli i ich analogów
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
NZ588372A (en) * 2005-09-09 2012-03-30 Novartis Ag Diphenyl ether or thioether derivatives for treatment of autoimmune diseases
JP5436860B2 (ja) 2005-11-09 2014-03-05 オニキス セラピューティクス， インク． 酵素阻害のための化合物
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
KR101441703B1 (ko) 2006-06-19 2014-09-17 오닉스 세라퓨틱스, 인크. 프로테아좀 저해를 위한 펩티드 에폭시케톤
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
CA2953372C (en) * 2006-09-26 2020-06-23 Novartis Ag Pharmaceutical composition comprising an s1p receptor modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
HUE035990T2 (en) 2007-03-29 2018-05-28 Daiichi Sankyo Co Ltd Pharmaceutical preparation
US8367617B2 (en) 2007-10-04 2013-02-05 Onyx Therapeutics, Inc. Crystalline peptide epoxy ketone protease inhibitors and the synthesis of amino acid keto-epoxides
EP2465492B1 (en) * 2007-10-12 2015-07-01 Novartis AG Compositions comprising sphingosine I phosphate (sip) receptor modulators
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
JP5452237B2 (ja) 2008-02-07 2014-03-26 杏林製薬株式会社 アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
DK2278960T4 (da) 2008-03-17 2020-01-27 Actelion Pharmaceuticals Ltd Dosisregimen til en selektiv sip1 receptoragonist
ES2676288T3 (es) * 2008-06-20 2018-07-18 Merck Patent Gmbh Matriz de comprimidos directamente compresible y rápidamente desintegrable
CN102076335A (zh) 2008-06-20 2011-05-25 诺瓦提斯公司 用于治疗多发性硬化的儿科组合物
BRPI0919183B8 (pt) * 2008-09-04 2021-05-25 Cargill Inc composição comprimível de eritritol, processo e uso do mesmo
AP2011005690A0 (en) 2008-10-21 2011-06-30 Onyx Therapeutics Inc Combination therapy with peptide epoxyketones.
CA2741974A1 (en) 2008-11-11 2010-05-20 Novartis Ag Salts of fingolimod
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
KR101393994B1 (ko) 2008-11-11 2014-05-14 노파르티스 아게 핑골리모드 ｈｃｌ의 결정질 형태
JP5305421B2 (ja) 2008-12-17 2013-10-02 第一三共株式会社 ジアミン誘導体の製造方法
WO2010082531A1 (ja) 2009-01-13 2010-07-22 第一三共株式会社 活性化血液凝固因子阻害剤
CN102348688B (zh) 2009-03-10 2014-07-09 第一三共株式会社 用于制备二胺衍生物的方法
WO2010104106A1 (ja) 2009-03-13 2010-09-16 第一三共株式会社 光学活性なジアミン誘導体の製造方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
JPWO2010147169A1 (ja) * 2009-06-18 2012-12-06 第一三共株式会社 溶出性の改善された医薬組成物
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
KR20130075723A (ko) 2010-03-01 2013-07-05 오닉스 세라퓨틱스, 인크. 면역프로테아좀 저해를 위한 화합물
ES2560955T3 (es) 2010-03-19 2016-02-23 Daiichi Sankyo Company, Limited Cristal de derivado de diamina y procedimiento de producción del mismo
BR112012023654B1 (pt) 2010-03-19 2022-04-12 Daiichi Sankyo Company, Limited Método para produzir grânulos contendo agente anticoagulante e método para produzir uma composição farmacêutica contendo o dito agente
EP2560619A2 (en) * 2010-04-22 2013-02-27 Ratiopharm GmbH A method of preparing an oral dosage form comprising fingolimod
BR112013000085B1 (pt) 2010-07-02 2022-04-19 Daiichi Sankyo Company, Limited Processos para a preparação de sal de derivado de diamina opticamente ativo
EP2646409A4 (en) 2010-11-25 2015-12-16 Shilpa Medicare Ltd FINGOLIMODE POLYMORPHS AND METHODS THEREOF
WO2012100043A2 (en) 2011-01-19 2012-07-26 Pathlogica LLC Controlled release oral pharmaceutical dosage forms comprising mgbg
AR085749A1 (es) 2011-04-01 2013-10-23 Novartis Ag Formulaciones
US9186333B2 (en) * 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
TWI578988B (zh) 2011-08-10 2017-04-21 第一三共股份有限公司 含二胺衍生物之醫藥組成物
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
EP2869820A4 (en) 2012-07-09 2016-02-17 Onyx Therapeutics Inc PRODRUGS OF PEPTIDEPOXIDE KETONE PROTEASE INHIBITORS
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
DK2943189T3 (da) 2013-01-08 2021-04-06 Pathologica Llc Mitoguazon til behandling af progressiv multipel sklerose
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
WO2014175287A1 (ja) * 2013-04-26 2014-10-30 国立大学法人 京都大学 脳動脈瘤の形成および／または増大の抑制若しくは縮小用医薬組成物
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
CA2920758A1 (en) * 2013-07-29 2015-02-05 Aizant Drug Research Solutions Pvt Ltd Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
CN106794159A (zh) * 2014-08-22 2017-05-31 广东东阳光药业有限公司 一种芬戈莫德固体组合物及其制备方法
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
CA2974375A1 (en) * 2015-01-20 2016-07-28 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
US20180042895A1 (en) 2015-02-26 2018-02-15 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) * 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
EP0627406B1 (en) 1992-10-21 1998-10-28 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
ES2230571T3 (es) 1995-12-28 2005-05-01 Mitsubishi Pharma Corporation `composicion farmaceutica destinada para la administracion topica que comprende el 2-amino-2-(2-(4-octilfenil)etil) propan-1,3-diol para el tratamiento de las enfermedades causadas por una alteracion inmunitaria.
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
AU735406B2 (en) * 1997-02-27 2001-07-05 Novartis Ag Pharmaceutical composition
CN1290819C (zh) 1997-04-04 2006-12-20 三菱制药株式会社 2－氨基丙烷－1，3－二醇化合物、其作为医药的用途及其合成中间体
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) 1999-06-30 2011-02-09 松森　　昭 ウイルス性心筋炎の予防または治療薬剤
EP1195165A4 (en) * 1999-07-12 2005-08-10 Ono Pharmaceutical Co FIBROSIS INHIBITORS CONTAINING THE ACTIVE INGREDIENT OF SPHINGOSINE A PHOSPHATE OR ITS RECEPTOR AGONISTS
KR100812578B1 (ko) 2000-07-13 2008-03-13 상꾜 가부시키가이샤 아미노알코올 유도체
AU8533101A (en) * 2000-08-31 2002-03-13 Merck & Co Inc Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
US7326801B2 (en) 2001-03-26 2008-02-05 Novartis Ag 2-amino-propanol derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
WO2003020313A1 (fr) 2001-09-04 2003-03-13 Ono Pharmaceutical Co., Ltd. Medicaments contre les maladies respiratoires renfermant un agent de regulation du recepteur de la sphingosine-1-phosphate
WO2003029184A1 (fr) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Derive d'ether de diaryle, son sel d'addition et son immunosuppresseur
BRPI0212894B8 (pt) 2001-09-27 2021-05-25 Kyorin Seiyaku Kk composto ou sal do mesmo farmaceuticamente aceitável e composição farmacêutica
EP1513522A2 (en) 2002-01-18 2005-03-16 Sri International Methods of treating conditions associated with an edg receptor
CA2472715A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
JP4709488B2 (ja) 2002-01-18 2011-06-22 メルク・シャープ・エンド・ドーム・コーポレイション Ｅｄｇ受容体作動薬としてのＮ−（ベンジル）アミノアルキルカルボン酸化合物、ホスフィン酸化合物、ホスホン酸化合物およびテトラゾール類
EP1469863A2 (en) 2002-01-18 2004-10-27 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
JP4917433B2 (ja) * 2004-07-16 2012-04-18 杏林製薬株式会社 効果的な医薬の使用法及び副作用発現の防御に関する方法

Also Published As

Publication number Publication date
US20170290787A1 (en) 2017-10-12
RU2475237C2 (ru) 2013-02-20
DE202004021680U1 (de) 2010-04-22
RU2012148593A (ru) 2014-05-20
JP2011006461A (ja) 2011-01-13
KR20050121712A (ko) 2005-12-27
IL242037A0 (en) 2015-11-30
SI1613288T1 (sl) 2009-04-30
MA27729A1 (fr) 2006-01-02
CA2521325A1 (en) 2004-10-21
US20140255497A1 (en) 2014-09-11
DK1613288T3 (da) 2009-03-23
WO2004089341A1 (en) 2004-10-21
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
DE122011100047I1 (de) 2011-12-15
IS2682B (is) 2010-10-15
NO334116B1 (no) 2013-12-16
US20130108675A1 (en) 2013-05-02
ES2556947T3 (es) 2016-01-21
FR2854073A1 (fr) 2004-10-29
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
CN1767819A (zh) 2006-05-03
HUE028247T2 (en) 2016-12-28
AR078781A2 (es) 2011-11-30
CY2011013I1 (el) 2014-04-09
HK1071685A1 (en) 2005-07-29
JP5495467B2 (ja) 2014-05-21
PE20150676A1 (es) 2015-05-17
NZ592339A (en) 2012-09-28
GB2400318B (en) 2005-08-10
MXPA05010860A (es) 2006-05-25
RU2010147000A (ru) 2012-08-10
EP2769713A1 (en) 2014-08-27
SI2316431T1 (sl) 2016-04-29
IE20040246A1 (en) 2004-12-15
BRPI0409250B8 (pt) 2022-01-18
HK1155647A1 (en) 2012-05-25
US20140011885A1 (en) 2014-01-09
CY2011013I2 (el) 2014-04-09
HRP20050886B1 (en) 2011-01-31
SG175449A1 (en) 2011-11-28
ES2228282A1 (es) 2005-04-01
ITMI20040682A1 (it) 2004-07-06
AT504853A2 (de) 2008-08-15
CY1117071T1 (el) 2017-04-05
GB0407819D0 (en) 2004-05-12
NO2011016I2 (no) 2012-08-27
HK1091114A1 (en) 2007-01-12
RU2009105403A (ru) 2010-08-27
HRP20100601A2 (hr) 2011-03-31
HRP20050886A2 (en) 2006-11-30
US20080311188A1 (en) 2008-12-18
KR101367574B1 (ko) 2014-02-25
CA2521325C (en) 2010-09-14
ZA200507394B (en) 2007-03-28
ECSP056090A (es) 2006-03-01
BE2011C030I2 (pt) 2023-03-07
PE20090743A1 (es) 2009-07-17
ES2320767T3 (es) 2009-05-28
IL197578A0 (en) 2011-07-31
PE20050396A1 (es) 2005-07-05
GB2400318A (en) 2004-10-13
JP2004307506A (ja) 2004-11-04
AU2004228929B2 (en) 2008-02-07
NO335120B1 (no) 2014-09-22
ES2228282B1 (es) 2006-02-16
AR043987A1 (es) 2005-08-17
US20090203798A1 (en) 2009-08-13
NO20100250L (no) 2006-01-09
KR20110005320A (ko) 2011-01-17
TW200503784A (en) 2005-02-01
EP1613288B1 (en) 2008-11-19
US8324283B2 (en) 2012-12-04
CL2004000745A1 (es) 2005-02-11
EP2319502A1 (en) 2011-05-11
PE20131352A1 (es) 2013-11-14
GR20040100121A (el) 2004-12-17
FR11C0036I1 (fr) 2011-10-14
CN101797241A (zh) 2010-08-11
LU91867I2 (fr) 2011-11-08
NZ542622A (en) 2009-01-31
FR11C0036I2 (fr) 2023-12-29
NO20131287L (no) 2006-01-09
TWI332847B (en) 2010-11-11
CA2707750A1 (en) 2004-10-21
US20110105620A1 (en) 2011-05-05
HUS1100016I1 (hu) 2016-08-29
BRPI0409250B1 (pt) 2017-07-11
AT501681A1 (de) 2006-10-15
AT501681B1 (de) 2012-04-15
EP2008650A2 (en) 2008-12-31
JP2013177404A (ja) 2013-09-09
TNSN05256A1 (en) 2007-07-10
JP5543298B2 (ja) 2014-07-09
DK2316431T3 (en) 2016-01-11
NO2011016I1 (no) 2011-09-19
US20220031609A1 (en) 2022-02-03
EP2316431B1 (en) 2015-09-30
IL170888A (en) 2010-06-16
GR1005052B (el) 2005-11-30
AU2004228929A1 (en) 2004-10-21
NO20055231D0 (no) 2005-11-07
HRP20100601B1 (hr) 2016-12-02
PE20130200A1 (es) 2013-03-09
MY141249A (en) 2010-03-31
US20060275357A1 (en) 2006-12-07
EP1613288A1 (en) 2006-01-11
CY1110260T1 (el) 2014-04-09
US20190175527A1 (en) 2019-06-13
LU91867I9 (pt) 2019-01-03
KR20120101148A (ko) 2012-09-12
ATE414508T1 (de) 2008-12-15
DE102004016947A1 (de) 2004-10-21
HRP20100600A2 (hr) 2011-03-31
US20200237690A1 (en) 2020-07-30
RU2475236C2 (ru) 2013-02-20
NZ586280A (en) 2011-12-22
AR078782A2 (es) 2011-11-30
CN1767819B (zh) 2010-07-28
CN101797241B (zh) 2013-03-27
EP2316431A1 (en) 2011-05-04
IL197578A (en) 2015-10-29
IS8885A (is) 2010-02-25
IS8114A (is) 2005-11-01
DE602004017847D1 (de) 2009-01-02
BRPI0409250A (pt) 2006-03-28
EP2008650A3 (en) 2011-04-27
PL1613288T3 (pl) 2009-07-31
FR2854073B1 (fr) 2008-03-14
NO329332B1 (no) 2010-09-27
RU2005134173A (ru) 2006-09-10
RU2358716C2 (ru) 2009-06-20
RU2010146697A (ru) 2012-05-27

Similar Documents

Publication Publication Date Title
HK1091114A1 (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
AU2003209475A1 (en) Fast melt multiparticulate formulations for oral delivery
AU2003246978A1 (en) Pharmaceutical compositions comprising cyclosporin for oral administration
NO20064808L (no) Orale matrixformuleringer med licarbazepin
IL164440A0 (en) New pharmaceutical composition containing fibanserin polymorph a
WO2004032866A3 (en) Therapeutic formulations
WO2008060546A3 (en) Oral formulations
WO2004012722A3 (en) Bicifadine formulation
UA87152C2 (ru) Твердая фармацевтическая композиция, содержащая миртазапин, и способ ее получения
EP1626697A4 (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION WITH LITHIUM CARBONATE
AU2003254672A1 (en) Dual-spike release formulation for oral drug delivery
TNSN06299A1 (en) Oral matrix formulations comprising licarbazepine
AU2002301781A1 (en) Solid pharmaceutical compositions for oral administration comprising itraconazole
MD20040296A (ro) Compoziţie farmaceutică, conţinând oxcarbazepină cu eliberare prelungită a ingredientului activ